LAUSR

Neuregulin 1 (NRG1) is an epidermal growth factor (EGF)‐like ligand that activates receptor tyrosine kinases of the ErbB family of receptors. NRG1 gene fusions, which are rare (<1%) but recurrent events in solid tumors, are an emerging oncogenic driver that is potentially actionable using ErbB‐targeted tyrosine kinase inhibitors. Largely characterized only in carcinomas, we describe three cases of NRG1‐rearranged sarcomas. The patients were all female, aged 32–47 years old. Two cases were deep‐seated tumors in the lower extremities (right thigh and calf); one case presented as a uterine mass. The tumors measured 9–11.5 cm in the greatest dimensions. Histologically, all three tumors were high‐grade spindle cell sarcomas composed of monomorphic spindle cells arranged in interlacing fascicles. The tumor cells were set in the loose collagenous stroma with branching, curvilinear thin‐walled vasculature in the background. Cytologically, the neoplastic cells displayed ovoid to fusiform nuclei with finely stippled chromatin, inconspicuous nucleoli, scant to moderate clear to eosinophilic cytoplasm, occasional cytoplasmic vacuoles, and elongated cytoplasmic processes. Mitotic activity was elevated (> 20/10 high power fields) and tumor necrosis was present. None of the tumors expressed lineage‐specific immunophenotypical markers. Targeted RNA‐sequencing uncovered gene fusions involving NRG1 and the 5′ untranslated regions of PPHLN1, HMBOX1, or MTUS1. In all cases, the C‐terminal EGF‐like domain of NRG1 was preserved in the predicted chimeric protein product. All three patients developed metastatic disease within 2 years from initial presentation and were alive with disease at last follow‐up (mean follow‐up period = 19 months). In conclusion, we present the first case series of NRG1‐rearranged sarcomas characterized by high‐grade fascicular spindle cell morphology, non‐specific immunoprofile, and aggressive clinical behavior. Further studies are needed to determine whether this distinct subgroup of spindle cell sarcomas are amenable to targeted therapies.